Search results
Showing 1 to 15 of 95 results for anticoagulation
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
Atrial fibrillation: current treatment with anticoagulation (IND128)
This indicator covers the percentage of patients who are currently treated with anticoagulation drug therapy in those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM82
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS93Show all sections
Sections for QS93
- List of quality statements
- Quality statement 1: Anticoagulation to reduce stroke risk
- Quality statement 2: Use of aspirin
- Quality statement 3: Discussing options for anticoagulation
- Quality statement 4: Anticoagulation control
- Quality statement 5: Referral for specialised management
- Quality statement 6 (developmental): Self-monitoring of anticoagulation
- Update information
This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS201Show all sections
Sections for QS201
- Quality statements
- Quality statement 1: Timing of pharmacological venous thromboembolism prophylaxis
- Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation
- Quality statement 3: Proximal leg vein ultrasound scan for a 'likely' deep vein thrombosis Wells score
- Quality statement 4: Venous thromboembolism anticoagulation review
- Quality statement 5: Follow-up for outpatients with low-risk pulmonary embolism
- Update information
- About this quality standard
Atrial fibrillation: admission rates (stroke, on anticoagulation) (IND38)
This indicator covers the proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were on anticoagulation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG55
Atrial fibrillation: admission rates (stroke, not on anticoagulation) (IND39)
This indicator covers the proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were not on anticoagulation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG56
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.